Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Immunovia AB ( (SE:IMMNOV) ) has issued an announcement.
Immunovia AB’s analytical validation study for its PancreaSure test has been recognized for scientific excellence by the Academy of Diagnostics & Laboratory Medicine (ADLM), receiving a Distinguished Abstract Award. This recognition underscores the test’s strong scientific foundation and is expected to boost physician confidence ahead of its US launch in September, potentially enhancing Immunovia’s market position in the early detection of pancreatic cancer.
More about Immunovia AB
Immunovia AB is a diagnostic company focused on increasing survival rates for pancreatic cancer patients through early detection. The company develops and commercializes blood-based tests to detect proteins and antibodies indicative of pancreatic cancer, collaborating with healthcare providers and experts to make these tests available to high-risk individuals. The USA is the largest market for pancreatic cancer detection, with an estimated 1.8 million high-risk individuals who could benefit from annual surveillance testing.
YTD Price Performance: -6.96%
Average Trading Volume: 3,789,748
Technical Sentiment Signal: Sell
Current Market Cap: SEK155.5M
For a thorough assessment of IMMNOV stock, go to TipRanks’ Stock Analysis page.